WATCH LIVE
timothy sykes logo
NMRA Stock Drops As Neumora Axes Failed Depression Drug Thumbnail
G Google News

NMRA Stock Drops As Neumora Axes Failed Depression Drug

JACK KELLOGG•UPDATED JUN. 28, 2026, 11:04 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Neumora Therapeutics Inc. stocks have been trading up by 8.61 percent after upbeat news on its neuroscience drug pipeline.

What Traders Need To Know

  • Phase 3 KOASTAL-2/3 navacaprant trials in major depressive disorder failed key endpoints, forcing Neumora Therapeutics Inc. to discontinue the program.
  • Following the KOASTAL-2/3 failures, H.C. Wainwright cut its price target from $18 to $7 but maintained a Buy rating after removing navacaprant from its model.
  • Needham lowered its target from $8 to $5, kept a Buy rating, and flagged a 35% workforce reduction designed to save about $10M a year.
  • Mizuho reduced its target from $6 to $4 after removing navacaprant but reiterated an Outperform rating, pointing to Neumora Therapeutics Inc.’s remaining early-stage pipeline.
  • Despite target cuts, Street consensus on NMRA is still overweight with an average target of $6.71, well above current trading levels near the mid-$1s.

Candlestick Chart

Weekly Update Jun 22 – Jun 26, 2026: On Sunday, June 28, 2026 Neumora Therapeutics Inc. stock [NASDAQ: NMRA] is trending up by 8.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Neumora Therapeutics (NMRA) is a clinical-stage CNS biotech with no product revenue and deeply negative profitability metrics (ROE ~-149%, ROA ~-108%), typical for an early platform but highlighting high equity burn. Q1 2026 operating cash outflow of ~$46M and net loss of ~$53M are only partially mitigated by a strong cash position of $147M, current ratio 5.1, and working capital of $123M. Leverage (total debt/equity 0.76) and high price-to-book (~6.4) underscore valuation risk versus book.

Technically, NMRA shows a nascent rebound this week: progression from 1.46–1.55 early in the week to a 1.64 close, taking out prior micro-resistance near 1.55 on increasing intraday participation. The dominant near-term trend has flipped from grinding downside to short-covering driven mean reversion, but the longer-term structure remains clearly bearish. A specific actionable level: 1.40–1.43 as a trading line in the sand; above it, tactical long trades toward 1.80–2.00, below it, expect renewed downside and liquidity vacuum.

Catalysts are currently adverse: navacaprant’s Phase 3 KOASTAL-2/3 failure, program discontinuation, and a 35% workforce reduction signal a reset story, despite analyst ratings remaining formally “Buy/Outperform” with slashed targets ($4–7 vs prior $6–18). Annualized $10M cost savings help but do not change the high cash-burn profile. Relative to biotech benchmarks, NMRA now trades as a high-risk, early-pipeline optionality play. Base case: capped upside with resistance at 2.00 and support at 1.40; risk/reward skew remains unfavorable.

More Breaking News

Quick Financial Overview

Neumora Therapeutics Inc. is trading deep in the penalty box after the navacaprant failure, with NMRA sitting around $1.46–$1.64 on recent weekly data. The weekly candles show tight ranges and closes clustered in the mid-$1s, which signals a pause after an initial selloff rather than active accumulation. Intraday, a 5-minute bar pushing from $1.50 to a $1.66 high and closing at $1.64 shows that bargain hunters are testing the waters, but one bar does not make a trend.

On the fundamentals, NMRA is a classic early-stage biotech profile: heavy losses, no visible revenue, and cash as the key asset. Q1 2026 net loss was about $53.5M with operating cash outflow of roughly $46.4M, pointing to a high burn rate. The balance sheet, however, shows cash of about $147.1M and working capital of roughly $123.3M, backed by a strong current ratio around 5.1, giving Neumora Therapeutics Inc. a decent near-term runway.

Key ratios underline the risk. Return on equity and return on assets are deeply negative, and price-to-book near 6.38 is rich for a name that just lost its lead Phase 3 asset. Enterprise value of about $210.2M versus heavy ongoing R&D spending of roughly $38.6M per quarter means traders are paying up for pipeline optionality, not current earnings power. With a 35% workforce cut expected to save around $10M annually, management is clearly in cash-preservation mode while it pivots away from navacaprant.

Conclusion

Neumora Therapeutics Inc. now trades as a reset story. The KOASTAL-2/3 Phase 3 failures erased the navacaprant upside that many traders were banking on, and the immediate response was a wave of price-target cuts from H.C. Wainwright, Needham, and Mizuho. At the same time, all three firms kept Buy or Outperform ratings, and the overall analyst stance on NMRA remains overweight with an average target of $6.71, far above the current price in the mid-$1s.

For traders, that disconnect between beaten-down price and still-bullish targets is the core setup. The chart shows stabilization after heavy damage, cost cuts should modestly extend the cash runway, and the remaining early-stage pipeline is now the entire bet. This is a high-risk, high-volatility name where position sizing and clear risk levels matter more than usual. In this kind of speculative biotech trading environment, discipline is crucial; as millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.”. As I tell my students, “When a biotech loses its lead asset, the stock doesn’t become untradeable — it just becomes a pure sentiment and catalyst vehicle, so you trade the chart and the cash runway, not the old story.”

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”